Atlas Trials

Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

2 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

RecordFirmDate
A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (NCT05071300)Ionis Pharmaceuticals, Inc.2022-01-04
NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (NCT04136184)Ionis Pharmaceuticals, Inc.2019-12-11

Track Hereditary Transthyretin-Mediated Amyloid Polyneuropathy automatically

Every clearance here is in the API, with alerts when new ones post.